PER-123-09已完成未知
A Randomised, Double-blind, Placebo-controlled, Parallel Design, Multicentre Study in Patients With Mild to Moderate Alzheimer´s Disease to Investigate the Effect on Cognitive Function as Measured by Repeated CogState Testing in Relation to Effects on Traditional Cognitive Measures After 12 Weeks
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 55 至 85（—）
- 性别
- All
入选标准
- •Provision of informed consent before the start of any procedure related to the study. Patients deemed unable to provide informed consent may be enrolled if the informed consent of the Legally Acceptable Representative has been obtained in accordance with local regulations.
- •Clinical diagnosis of probable AD according to the NINCDS-ADRDA criteria.
- •History of progressive impairment of memory and other cognitive functions for at least 12 months
- •Hachinski Ischemia Score <4
- •Computed Tomography (CT) or Magnetic Resonance Exam (MRI) within the last 6 months (performed after the onset of dementia) consistent with the diagnosis of AD. If the CT / MRJ test is older than 6 months, the patient will need to renew the CT / MRI to confirm the diagnosis.
- •MMSE score from 16 to 24.
- •Men and women, 55-85 years, including the day of enrollment
- •The patient must live with an appropriate caregiver at home, or in a community accommodation. The caregiver should be able to accompany the patient to the visits to the center or attend the study visits in the patient´s case. The same caregiver is needed for visits where ADCS-CGIC is evaluated.
- •The patient and the caregiver understand and are capable and wish to meet all the requirements of the study, judging by the investigator.
- •The patient and the caregiver should understand, speak and read the local language.
- •A body mass index (BMI = weight / height) of 18-35 kg / m2 according to the researcher´s calculations during enrollment.
排除标准
- •Possible, probable or definitive vascular dementia in accordance with the criteria of the National Institute of Neurological Disorders and Stroke Association-Association Internationale pour la Recherche et l´Enseignement en Neurosciences (NINDS-AIREN)
- •Significant neurological disease or dementia other than AD, for example, mixed dementia, frontotemporal dementia and Parkinson´s disease, which may affect cognition or the ability to complete the study.
- •Current major depressive disorder or other major psychiatric disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders Edition (DSM-IV).
- •Clinically significant or unstable current respiratory disease, gastrointestinal disease, heart disease, cerebrovascular disease, hematological disease, liver disease, kidney disease, urogenital disease, or other major disease, as judged by the researcher.
- •Current systemic disease that, at the discretion of the researcher, probably impairs or affects the safety of the participant, influences cognitive evaluations or affects the ability to complete the study.
- •History of seizures or loss of consciousness within 6 months before enrollment.
- •History of any malignant disease within the last 5 years, with the exception of minor superficial cutaneous disease (ie, basal cell carcinoma and squamous cell carcinoma).
- •Myocardial infarction or acute coronary syndrome within the last year.
- •Clinically significant ECG abnormalities according to the investigator´s criteria based on the evaluation by a centrally located experienced cardiologist who interprets the ECG.
- •Prolonged QTcF> 450 msec or shortened QTcF <350 msec or family history of long QT syndrome.
- •Clinically significant abnormal findings on the physical examination, vital signs, or clinical biochemistry that may affect the patient´s ability to complete the study procedures, participant safety, or interpretation of data at the investigator´s discretion.
- •Women of childbearing age (for example, postmenopausal defined as amenorrhea for at least 12 months after cessation of all periods or documentation of irreversible surgical sterilization due to hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but without tubal ligation)
- •Male patients who plan to have a child or donate sperm within 3 months after the last intake of the study drug.
- •Known or suspected alcohol and / or drug abuse as defined by the DSM-IV criteria and that is not in complete remission.
- •Vision or hearing injury that makes cognitive tests difficult as the researcher considers.
- •Known hypersensitivity to piperidine derivatives.
- •Previous use of memantine or acetylcholinesterase inhibitors (AchEI).
- •Use of any potent CYP3A4 or Cyp2D6 enzyme inhibitor or inducer during the last 4 weeks before randomization (see Table 4 for further clarification)
研究者
相似试验
进行中（未招募）
不适用
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with Moderate to Severe COPD - PACEChronic Obstructive Pulmonary DiseaseEUCTR2005-004110-32-DEAstraZeneca AB190
进行中（未招募）
1 期
Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabètes Post Worsening Heart Failure (SOLOIST-WHF Trial)Cardiovascular diseasesMedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-003510-16-FRSanofi-aventis Recherche & Développement6,667
进行中（未招募）
1 期
Effect of Efpeglenatide on Cardiovascular OutcomesType 2 diabetes mellitusMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-002954-35-SKsanofi-aventis recherche & développement5,000
进行中（未招募）
1 期
Efficacy and Safety of Sotagliflozin versus Placebo in Subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control while Taking Insulin Alone or with Other Oral Antidiabetic AgentsType 2 diabetes mellitusMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-001804-43-HUSanofi-aventis Recherche & Développement800
进行中（未招募）
不适用
A study on the safety and effectivenes of study drug in reducing the number of seizures in subjects with epilepsy. The drug will be studied in young people aged from 12 to less than 18 years. It will assess if the drug has any effect on the ability to know, learn, perceive, recognize, remember, think and understand. Also, if it has effects on growth and development.Inadequately controlled partial onset seizuresEUCTR2010-018518-56-HUEisai Limited132